Tag: Wuhan Zhong Yuan Rui De Biologics
CSL to buy majority stake in a leading Chinese plasma fractionator
Australian biotech firm CSL has agreed to acquire an 80% stake in China’s plasma-derived therapies manufacturer Wuhan Zhong Yuan Rui De Biologics (Ruide) in...
Featured Article
How AI-enabled cloud ERP is redefining growth for manufacturing leaders
Manufacturing leaders are entering a new phase of supply chain transformation, where growth is increasingly determined by how quickly and intelligently organisations can respond to change.
